The effect of rosiglitazone on insulin sensitivity and mid-thigh low-density muscle in patients with Type 2 diabetes

Diabetic Medicine

Volumn 27, Issue 1, 2010, Pages 30-36

  Nam, J S ^a   Nam, J Y ^b   Yoo, J S ^a   Cho, M ^a   Park, J S ^a   Ahn, C W ^a   Cha, B S ^a   Lee, E J ^a   Lim, S K ^a   Kim, K R ^a   Lee, H C ^a  

^a Yonsei University College of Medicine   (South Korea)

^b National Health Insurance Corporation   (South Korea)

Author keywords

Adiponectin; Insulin resistance; Type 2 diabetes; Visceral fat

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; FAT; GLIMEPIRIDE; LEPTIN; RESISTIN; ROSIGLITAZONE; SULFONYLUREA;

ABDOMINAL FAT; ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECT; FEMALE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIPID STORAGE; MALE; METABOLISM; MUSCLE; NON INSULIN DEPENDENT DIABETES MELLITUS; THIGH; TREATMENT DURATION;

ADIPOKINES; ADULT; AGED; BODY FAT DISTRIBUTION; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; MUSCLE, SKELETAL; THIAZOLIDINEDIONES;

EID: 73949138029     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2009.02897.x     Document Type: Article

References (34)

1. DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular complication for identifying diabetes genes. Diabetes Rev 1997 5 : 177 269.
2. Petersen KF, Shulman GI. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am J Cardiol 2002 90 : 11G 18G.
3. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y et al. Mechanism by which fatty acid inhibits insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidyl-linositol 3-kinase activity in muscle. J Biol Chem 2002 277 : 50230 50236.
4. Kelley DE, Goodpaster B, Wing RR, Simoneau JA. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol 1999 277 : E1130 E1141.
5. Goodpaster BH, Kelley DE, Thaete FL, He J, Ross R. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol 2000 89 : 104 110.
6. Perseghin G, Scifo P, De Cobelli F, Pagliato E, Battezzati A, Arcelloni C et al. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 1999 48 : 1600 1606.
7. Kahn CR, Chen L, Cohen SE. Unraveling the mechanism of action of thiazolidinediones. J Clin Invest 2000 106 : 1305 1307.
8. Forouhi NG, Jenkinson G, Thomas EL, Mullick S, Mierisona S, Bhonsle U et al. Relation of triglyceride stores in skeletal muscle cells to central obesity and insulin sensitivity in European and South Asian men. Diabetologia 1999 42 : 932 935.
9. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002 51 : 797 802.
10. Rasouli N, Raue U, Miles LM, Lu T, Di Gregorio GB, Elbein SC et al. Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab 2004 288 : E930 E934.
11. Muurling M, Mensink RP, Pijl H, Romijn JA, Havekes LM, Voshol PJ. Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice. Metabolism 2003 52 : 1078 1083.
12. Petersen KF, Krssak M, Inzucchi S, Cline GW, Dufour S, Shulman GI. Mechanism of troglitazone action in type 2 diabetes. Diabetes 2000 49 : 827 831.
13. Shimomura H, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999 401 : 73 76.
14. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001 7 : 941 946.
15. Chao L, Marcus-Samuels B, Mason MM, Moitra J, Vinson C, Arioglu E et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 2000 106 : 1221 1228.
16. Loviscach M, Rehman N, Carter L, Mudaliars S, Mohadeen P, Ciaraldi TP et al. Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action. Diabetologia 2000 43 : 304 311.
17. Lapsys NM, Kriketos AD, Lim-Fraser M, Poynten AM, Lowy A, Furler SM et al. Expression of genes involved in lipid metabolism correlate with peroxisome proliferators-activated receptor expression in human skeletal muscle. J Clin Endocrinol Metab 2000 85 : 4293 4297.
18. Goodpaster BH, Kelley DE, Wing RR, Meier A, Thaete FL. Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 1999 48 : 839 847.
19. Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima M et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999 22 : 908 912.
20. de Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W, Laurent D et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 2001 50 : 1863 1871.
21. Thomas EL, Potter E, Tosi I, Fitzpatrick J, Hamilton G, Amber V et al. Pioglitazone added to conventional lipid-lowering treatment in familial combined hyperlipidaemia improves parameters of metabolic control: relation to liver, muscle and regional body fat content. Atherosclerosis 2007 195 : e181 e190.
22. Kim D, Nam S, Ahn C, Kim K, Yoon S, Kim K et al. Correlation between midthigh low density muscle and insulin resistance in obese nondiabetic patients in Korea. Diabetes Care 2003 26 : 1825 1830.
23. Clinton RB, Mitchell JA, Andrew LC, David GN, Arend B, Adamandia DK et al. Muscle oxidative capacity is a better predictor of insulin sensitivity than lipid status. J Clin Endocrinol Metab 2004 88 : 5444 5451.
24. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993 259 : 87 91.
25. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM et al. The hormone resistin links obesity to diabetes. Nature 2001 409 : 307 312.
26. Mukhtar R, Reckless JPD. Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone. Diabet Med 2005 22 : 1 20.
27. Nolan JJ, Olefsky JM, Nyce MR, Considine RV, Caro JF. Effect of troglitazone on leptin production: studies in vitro and in human subjects. Diabetes 1996 45 : 1276 1278.
28. Wang Q, Dryden S, Frankish HM, Bing C, Pickavance L, Hopkins D et al. Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y. Br J Pharmacol 1997 122 : 1405 1410.
29. Shimizu H, Tsuchiya T, Sato N, Shimomura Y, Kobayashi I, Mori M. Troglitazone reduces leptin concentration but increases hunger in NIDDM patients. Diabetes Care 1998 21 : 1470 1474.
30. Youn BS, Yu KY, Park HJ, Nam SL, Min SS, Youn MY et al. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004 89 : 150 156.
31. Majuri A, Santaniemi M, Rautio K, Kunnari A, Vartiainen J, Ruokonen A et al. Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. Eur J Endocrinol 2007 156 : 263 269.
32. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP et al. Glycemic durability of rosiglitazone, metformin, or glyburide monother. N Engl J Med 2006 355 : 2427 2443.
33. Bonora E, Moghetti P, Zancanaro C, Cigolini M, Querena M, Cacciatori V et al. Estimates of in vivo insulin action in man: comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clamp studies. J Clin Endocrinol Metab 1989 68 : 374 378.
34. Gelding SV, Robinson S, Lowe S, Niththyananthan R, Johnston DG. Validation of the low dose short insulin tolerance test for evaluation of insulin sensitivity. Clin Endocrinol 1994 40 : 611 615.